Skip to content

Compass Therapeutics, Inc.

CMPX· NasdaqCore metricsCIK 1738021

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -1.60%
Market cap
$147.13M
180.09M shares
Filings
362
$0.00
FY 2025−100.0% FY25 yoy
-$27.17M
Q3 2026N/M FY25 yoy
-$28.80M
Q3 2026N/M FY25 yoy
-$48.69M
Q3 2026derivedN/M FY25 yoy
-$0.07
Q1 2022N/M FY21 yoy
$41.47M
Q3 2026−29.5% FY25 yoy
$147.13M
—
—
1.0×
-33.42%
—

FY2025 figures · derived

Price

$0.81782.39%$3.823past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$0.00FY 2025
$850.00K0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$0reported
FY 20242024-12-31$850,000reported
FY 20232023-12-31$0reported

Biological products, except diagnostic substances

Compass Therapeutics, Inc. is the 100th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR